www.fdanews.com/articles/157441-results-from-phase-iii-study-of-ivacaftor-monotherapy-showed-statistically-significant-improvements-in-lung-function-in-people-with-non-g551d-gating-mutations
Results From Phase III Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People With Non-G551D Gating Mutations
July 30, 2013
Vertex announced positive results from its Phase III trial of Kalydeco (ivacaftor) in cystic fibrosis patients ages 6 and older who possess at least one gating mutation other than G551D.
The Wall Street Journal
The Wall Street Journal